同型半胱氨酸、维生素D、C、E、B12及叶酸与胃癌关系的研究进展北大核心

胃癌作为临床最常见的肿瘤之一,常因确诊疾病较晚而影响治疗效果,胃镜活检后的病理虽然作为确诊的金标准,但是由于此方式过程痛苦,操作复杂,费用较高,且具有侵入性,可能会导致患者拒绝操作而难普及于临床,因此积极找寻胃癌有效的监测指标十分必要。近年来,很多学者研究维生素与胃癌的相关关系,并试图通过摄取某些维生素降低胃癌发生率,延缓病情及改善预后,也有通过检测血清中维生素的水平给早期胃癌的诊断提供帮助。本文就同型半胱氨酸、维生素D、维生素C、维生素E、维生素B12及叶酸在胃癌中的作用机制,及其在血清中水平与胃癌关系的相关研究进展进行简要综述,为临床胃癌诊疗提供新思路。     

Surgical blood ordering schedule for better inventory management: An experience from a tertiary care transfusion center

BackgroundOverordering of blood has been a challenge faced by the blood bank staff. The present study addresses the role of maximum surgical blood ordering schedule (MSBOS) in optimizing the blood inventory management.MethodsThe blood requests for elective surgical procedures from various surgical departments were reviewed to constitute MSBOS. Transfusion profile was assessed using crossmatch to transfused units (C/T) ratio, transfusion probability (TP), and transfusion index (TI). A cutoff of 0.3 and 5% value of TI and TP, respectively, was considered to decide on the type of crossmatch. The efficacy of MSBOS implementation has been determined prospectively by unpaired t test using SPSS software, version 20 (IBM, USA).ResultsA total of 2674 patients were studied. Overall red cell usage rate was 15%. The comprehensive C/T ratio was 4.57. The C/T ratios for the various departments ranged from 1 to 8.5 (adjusted C/T ratio). Highest C/T ratio was observed for surgical procedures performed in the specialties of otorhinolaryngology and urology. A C/T ratio greater than 5 was noted in 30.4% of different types of surgical procedures. Of the 176 different types of elective surgical procedures studied, type and screen protocol was applicable for 75.5% (133) of the procedures. After implementation of MSBOS, the number of crossmatches reduced by 2152 and total working time saved in our laboratory is close to 75,320 man hours.ConclusionMSBOS helps in identifying the common surgical procedures with low TP and is one of the efficient tools in preventing the overordering of the blood.     

Viral hepatitis: Past,present, and future

Each hepatitis virus—Hepatitis A, B, C, D, E, and G—poses a distinct scenario to the patient and clinician alike. Since the discovery of each virus, extensive knowledge regarding epidemiology, virologic properties, and the natural clinical and immunologic history of acute and chronic infections has been generated. Basic discoveries about host immunologic responses to acute and chronic viral infections, combined with virologic data, has led to vaccines to prevent Hepatitis A, B, and E and highly efficacious antivirals for Hepatitis B and C. These therapeutic breakthroughs are transforming the fields of hepatology, transplant medicine in general, and public and global health. Most notably, there is even an ambitious global effort to eliminate chronic viral hepatitis within the next decade. While attainable, there are many barriers to this goal that are being actively investigated in basic and clinical labs on the local, national, and international scales. Herein, we discuss pertinent clinical information and recent organizational guidelines for each of the individual hepatitis viruses while also synthesizing this information with the latest research to focus on exciting future directions for each virus.     

Preoperative comprehensive malignancy risk estimation for thyroid nodules: Development and verification of a network-based prediction model

BackgroundIn order to avoid excessive treatment of thyroid nodules in the clinic, it is necessary to find a simple and practical analysis method to comprehensively and accurately reflect benign or malignant thyroid nodules. This study aimed to construct and validate a comprehensive and reliable network-based predictive model using a variety of imaging and laboratory criteria for thyroid nodules to stratify the risk of malignancy prior to surgery.MethodsWe retrospectively analyzed data from patients who underwent surgical treatment for thyroid nodules at the Thyroid and Breast Diagnosis and Treatment Center of Weifang Hospital of Traditional Chinese Medicine between January 2018 and December 2020. Binary logical regression analysis was performed to predict whether nodules were malignant or benign. The developmental dataset included 457 patients (January 2018–December 2020). The validation set included separate data points (n = 225, January 2018–December 2020).ResultsIn this study, criteria that showed significant predictive value for malignant nodules included TI-RADS: 4b (p = 0.065); Bethesda IV, Bethesda V, Bethesda VI (P < 0.0001); BRAF^V600E mutation (P < 0.0001); Calcitonin>5 pg/ml (p = 0.0037); and FNA-Tg>30 ng/ml (p = 0.0003). A 10-grade risk scoring system was developed. The risk of malignancy risk ranged from 2.06% to 100% and was positively associated with increasing risk grade. The areas under the receiver-operating characteristic curve of the development and validation sets were 0.972 and 0.946, respectively.ConclusionA simple, comprehensive and reliable web-based predictive model was designed using a variety of imaging and laboratory criteria to stratify thyroid nodules by probability of malignancy.     

2011—2020年平顶山市 乙型病毒性肝炎流行病学特征分析 时空分布特征及与性别、年龄变化情况

[摘要]　目的　分析河南省平顶山市2011—2020年乙型病毒性肝炎（乙肝）流行病学特征，为调整本市的乙肝防控策略和措施提供科学依据。方法?通过中国疾病预防控制信息系统收集网络直报的平顶山市2011—2020年乙肝病例数据，采用描述性流行病学方法进行分析。结果?2011—2020年平顶山市共报告27 078例乙肝病例，年平均发病率为67.47/10万，2016—2020年期间的年平均发病率（36.95/10万）较2011—2015年期间（98.46/10万）明显下降（χ2=5628.949，P=0.000）；急、慢性乙肝发病率分别为8.50/10万和57.88/10万；0～14岁以下儿童年平均发病率最低，为2.89/10万，随着年龄的增长，乙肝报告发病率呈现逐渐增高的趋势（χ2趋势=4644.258，P=0.000）；男性年平均发病率（71.21/10万）高于女性（63.44/10万）（χ2=89.803，P=0.000）；2016—2020年间发病率居前3位的分别为宝丰县（58.40/10万）、舞钢市（57.83/10万）、石龙区（56.50/10万），均为城郊地区。结论?平顶山市2011—2020年乙肝报告发病率呈下降趋势，尤以0～14岁以下儿童发病率较低。建议进一步加强成人乙肝防控工作，并重点加强宝丰县和舞钢市等高风险地区的防控工作。     

橙皮苷在低压低氧所致大鼠视网膜抗氧化能力和炎症介质调控改变中的作用

目的　探讨橙皮苷（HSD）在低压低氧所致大鼠视网膜抗氧化应激能力及炎性介质调控改变中的干预作用。方法　取健康雄性清洁级成年SD大鼠72只（144眼），随机分为对照组、低压低氧组及HSD干预组，每组24只（48眼）。对照组大鼠饲养于常氧环境，低压低氧组及HSD干预组大鼠放置于模拟海拔5000 m高度的低压氧舱内喂养。HSD干预组大鼠给予HSD灌胃，对照组和低压低氧组大鼠给予生理盐水，各组大鼠每天等量灌胃一次，连续7 d。通过HE染色光镜下观察大鼠视网膜组织形态变化；采用酶联免疫吸附(ELISA)法检测大鼠视网膜谷胱甘肽(GSH)和半胱氨酸(Cys)蛋白浓度、丙二醛（MDA）含量以及肿瘤坏死因子-α（TNF-α）活性；Western-blot检测大鼠视网膜核因子-κB p65（NF-κB p65）和细胞色素C（Cyto-C)蛋白表达水平。结果　光镜下观察可见，与对照组相比，低压低氧组大鼠出现视网膜水肿，HSD干预组较低压低氧组大鼠视网膜水肿程度减轻。与对照组相比，低压低氧组大鼠视网膜中GSH蛋白浓度和Cys蛋白浓度降低，MDA含量升高，差异均有统计学意义（均为P<0.001）；与低压低氧组相比，HSD干预组提高了GSH蛋白浓度和Cys蛋白浓度，降低了MDA含量，GSH蛋白浓度和MDA含量两组相比差异均有统计学意义（均为P<0.001），Cys蛋白浓度两组相比差异无统计学意义（P>0.05）。与对照组相比，低压低氧组大鼠视网膜中NF-κB p65蛋白表达水平和TNF-α活性升高，差异均有统计学意义（P<0.01、 P<0.001）；与低压低氧组相比，HSD干预组大鼠视网膜中NF-κB p65蛋白表达水平和TNF-α活性降低，差异均有统计学意义（P<0.05、P<0.001）。与对照组相比，低压低氧组大鼠视网膜Cyto-C蛋白表达水平明显升高，差异有统计学意义（P<0.01）；与低压低氧组相比，HSD干预组大鼠视网膜中Cyto-C蛋白表达水平降低，差异有统计学意义（P<0.05）。结论　HSD能够通过提高大鼠视网膜抗氧化应激能力、抑制炎症介质释放以及减少线粒体损伤而发挥保护视网膜功能的作用。     

The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study

BackgroundDuring the COVID-19 pandemic, the number of hepatitis B virus (HBV) vaccinations among men who have sex with men (MSM) has been considerably lower than before the pandemic. Moreover, less frequent HBV testing and a reduction in numbers of sex partners have been reported. We assessed the impact of these COVID-19-related changes on HBV transmission among MSM in the Netherlands.MethodsWe estimated the changes in sexual activity, HBV testing, and HBV vaccination among MSM during the pandemic from Dutch data. We used a deterministic compartmental model and investigated scenarios with small or large declines in sexual activity, testing, and vaccination for the current phase of the pandemic (without available data). We examined the increase in HBV vaccinations needed to prevent further increase in HBV incidence.ResultsWith a decrease in numbers of sex partners of 15–25% during the first lockdown and 5% during the second lockdown, we found a decline of 6.6% in HBV incidence in 2020, despite a >70% reduction in HBV testing and vaccination during the first lockdown. With numbers of sex partners rebounding close to pre-pandemic level in 2021, and a reduction of 15% in testing and 30% in vaccination in 2021, we found an increase of 1.4% in incidence in 2021 and 3.1% in 2026. With these changes, an increase of ≥60% in HBV vaccinations in 2022 would be needed to bring the HBV incidence in 2023 back to the level that it would have had if the COVID-19-related changes had not occurred.ConclusionsDespite reductions in sexual activity during the COVID-19 pandemic, the decrease in HBV vaccinations may result in a small increase in HBV incidence after 2021, which may persist for years. It is important to restore the vaccination level and limit further increase in HBV transmission among MSM.     

Immunity of two novel hepatitis C virus polyepitope vaccines

Hepatitis C virus (HCV) infection remains a serious public health burden around the world. So far there is no effective vaccine against this virus. Neutralizing antibody (NAb) responses to the epitopes within HCV E1 and E2 proteins are related to the resolution of hepatitis C infection. E. coli heat-labile enterotoxin B subunit (LTB) has been described as potent immunity adjuvants. In this study, we constructed recombinant pET vectors: pET-R9-Bp (B cell polyepitopes) expressing 7 epitopes from HCV E1 and E2 proteins including R9 (E2_384-411aa)-Bp (E1_313-327aa-E2_396-424aa-E2_436-447aa-E2_523-540aa-E2_610-627aa-E2_631-648aa) and pET-LTB-R9-Bp expressing LTB adjuvant in combination with R9-Bp. Recombinant proteins R9-Bp and LTB-R9-Bp were expressed successfully in E. coli and purified by the Ni-NTA column. Both R9-Bp and LTB-R9-Bp in BALB/c mice induced robust humoral immune response in the context of intraperitoneal or intramuscular immunization but not oral immunization. Intraperitoneal administration of LTB-R9-Bp induced a higher antibody titer (peak titer: 1:341000) than that of R9-Bp (peak titer: 1:85000) after the second boost (P = 0.0036 or 0.0002). However, comparable antibody peak titers were elicited for both R9-Bp and LTB-R9-Bp in intramuscular immunization albeit with significant difference (P = 0.0032) a week after the second boost. In addition, both R9-Bp and LTB-R9-Bp induced the secretion of cytokines including IFN-γ and IL-4 at similar levels. anti-sera induced by both R9-Bp and LTB-R9-Bp recognized native HCV E1 and E2 proteins. Moreover, these HCV-specific antisera inhibited significantly the entry of HCV (P < 0.0001). Taken together, these findings showed that E. coli-based both R9-Bp and LTB-R9-Bp could become promising HCV vaccines.     

Efficacy of an eConsult service to cure hepatitis C in primary care

In 2016, an eConsult service was developed within a safety net health system to expand access to hepatitis C (HCV) treatment in the primary care setting. The eConsult system provides individualized treatment recommendations from specially trained primary care pharmacists and primary care physicians to primary care providers with less experience in the rapidly changing treatment of HCV. Since its launch, this service has had a large impact in expanding care to a largely homeless and low-income urban population within our health system. We now aim to evaluate its efficacy in curing HCV. In this retrospective cohort study, we describe rates of sustained virologic response 12 weeks after treatment completion (SVR12) for those who received primary care-based HCV treatment through the eConsult system with those who were treated in primary care independent of an eConsult from 2017 to 2019. We found there was no significant difference in the proportion of patients who achieved SVR12 between the two groups. Overall, >90% of patients who received treatment achieved SVR12. Approximately 40% of patients treated for HCV received an eConsult, suggesting utility of the eConsult in expanding access and coordinating treatment for patients within our network.